Characterization of lung cancers in patients with BRCA germline variants: A multicenter series.
BRCA1
BRCA2
Genetic susceptibility to cancer
Germline variants
Lung cancer
Journal
Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
03
03
2022
revised:
24
07
2022
accepted:
02
09
2022
pubmed:
27
9
2022
medline:
21
10
2022
entrez:
26
9
2022
Statut:
ppublish
Résumé
BRCA1 and BRCA2 (BReast CAncer susceptibility genes) are two tumor-suppressor genes associated with the hereditary breast and ovarian cancer susceptibility syndrome. Recent studies also suggest an increased lung adenocarcinoma risk in carriers. We conducted a multi-center retrospective study in 18 different French pulmonology and/or oncology departments on medico-administrative and clinical data prospectively collected in the Clinical Data Warehouse (CDW) of Greater Paris University Hospitals (Assistance Publique-Hôpitaux de Paris, AP-HP). Clinical characteristics and outcomes of patients with LC and a previously known BRCA1/2gl variant were retrospectively evaluated. 17 patients with LC and known BRCA1/2gl variant were included. Patients were most women, former smokers with localized disease and BRCA2 variants. All LC were adenocarcinoma. For patients with medical history of cancer, median time from the first cancer in the BRCA spectrum and the LC occurrence was 20 years. Median disease-free survival (DFS) and overall survival (OS) in localized tumor (Stage I and II) was not reached and 78.6 months, respectively. In advanced cancer (Stade III and IV) median progression free survival was 9.7 months and median OS was 17.8 months. Univariate OS and DFS/PFS analyses by BRCA status did not find significant differences. Results seem to show particular LC features in carriers of BRCA2 variants: adenocarcinoma subtype, woman, former or non-smoker.
Identifiants
pubmed: 36156322
pii: S0169-5002(22)00616-X
doi: 10.1016/j.lungcan.2022.09.002
pii:
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 protein, human
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-70Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: J. Cadranel reports fees for participation on boards of experts for the development of cancer drugs from AZ, BMS, Jansen, MSD, Novartis, Lilly, Pfizer, Roche and Takeda. PR Benusiglio has received honoraria from AstraZeneca and MSD, the manufacturers of the PARP-inhibitor olaparib.